Formulation and evaluation of ondansetron nasal delivery systems

被引:43
作者
Cho, Eunsook [2 ]
Gwak, Hyesun [1 ]
Chun, Inkoo [2 ]
机构
[1] Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea
[2] Dongduk Womens Univ, Coll Pharm, Seoul 136714, South Korea
关键词
ondansetron hydrochloride; vehicles; permeation rate; lag time; phamacokinetic parameters;
D O I
10.1016/j.ijpharm.2007.07.028
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
This study aimed to formulate and evaluate nasal delivery systems containing ondansetron hydrochloride. In the in vitro study, the permeation rate with the addition of 10% polyethylene glycol 300 (PEG 300) to aqueous solution containing 0.01% benzalkonium chloride (BC) and 10% sulfobutylether beta-cyclodextrin sodium salt (SBCD) was somewhat more rapid up to 1.5 h compared to the addition of 10% PG. The permeation flux increased as the drug concentration increased regardless of the vehicles used. The addition of nicotinamide or chitosan to aqueous drug solution (40 mg/ml) with 10% PEG 300 and 0.01% BC rather decreased permeation rate and delayed lag time. Even though cyclodextrins including SBCD or dimethyl-B-cyclodextrin failed to show permeation enhancing effects of ondansetron hydrochloride, the addition of 10% SBCD to aqueous solution containing 10% PEG 300 and 0.01% BC could be a good candidate for ondansetron nasal delivery systems because of its safety profile, stable storage in refrigerator and solubilizing effect. With the above formulation, the nasal delivery system increased AUC(0-2h) and C-max by 2.1 and 1.7 times compared to those of oral delivery, respectively while there was no difference found in AUC(0-2h) with intravenous administration. Therefore, the nasal delivery system of ondansetron hydrochloride formulated in this study was feasible for nasal administration. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:101 / 107
页数:7
相关论文
共 26 条
[1]
The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa [J].
Asai, K ;
Morishita, M ;
Katsuta, H ;
Hosoda, S ;
Shinomiya, K ;
Noro, M ;
Nagai, T ;
Takayama, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 246 (1-2) :25-35
[2]
Effects of physicochemical properties and other factors on systemic nasal drug delivery [J].
Behl, CR ;
Pimplaskar, HK ;
Sileno, AP ;
deMeireles, J ;
Romeo, VD .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 29 (1-2) :89-116
[3]
BLACKWELL CP, 1989, EUR J CANCER CLIN ON, V25, pS21
[4]
BUTCHER ME, 1993, ONCOLOGY-BASEL, V50, P191
[5]
Chien Y. W., 1989, NASAL SYSTEMIC DRUG
[6]
Choi JW, 2001, ANN CLIN LAB SCI, V31, P151
[7]
Pharmacokinetics of ondansetron in patients with hepatic insufficiency [J].
Figg, WD ;
Dukes, GE ;
Pritchard, JF ;
Hermann, DJ ;
Lesesne, HR ;
Carson, SW ;
Songer, SS ;
Powell, R ;
Hak, LJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (03) :206-215
[8]
In vitro percutaneous absorption of ondansetron hydrochloride from pressure-sensitive adhesive matrices through hairless mouse skin [J].
Gwak, HS ;
Oh, IS ;
Chun, IK .
ARCHIVES OF PHARMACAL RESEARCH, 2003, 26 (08) :644-648
[9]
Transdermal delivery of ondansetron hydrochloride: Effects of vehicles and penetration enhancers [J].
Gwak, HS ;
Oh, IS ;
Chun, IK .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2004, 30 (02) :187-194
[10]
EFFECT OF VISCOSITY ON THE PHARMACOKINETICS AND BIOLOGICAL RESPONSE TO INTRANASAL DESMOPRESSIN [J].
HARRIS, AS ;
OHLIN, M ;
SVENSSON, E ;
LETHAGEN, S ;
NILSSON, IM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (06) :470-471